Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2356-2360

  Lenaerts, Anne M J A ^b   Chase, Sharon E ^b   Chmielewski, Alex J ^b   Cynamon, Michael H ^a  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LONG TERM CARE; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SPLEEN; TUBERCULOSIS;

EID: 0032846475     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2356     Document Type: Article

References (23)

1. Brooks, J. V., and I. M. Orme. 1998. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob. Agents Chemother. 42:3047-3048.
2. Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. J. Respir. Crit. Care Med. 150:1355-1362.
3. Cynamon, M. H. 1985. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob. Agents Chemother. 28:440-441.
4. Dhillon, J., J. M. Dickinson, J. A. Guy, T. K. Ng, and D. A. Mitchison. 1992. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber. Lung Dis. 73:116-123.
5. Dhillon, J., and D. A. Mitchison. 1992. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am. Rev. Respir. Dis. 145:212-214.
6. Dixon, B. 1998. Viable but nonculturable. ASM News 64:372-373.
7. Gangadharam, P. R. J. 1995. Mycobacterial dormancy. Tuber. Lung Dis. 76:477-479.
8. Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am. J. Respir. Crit. Care Med. 157:1436-1440.
9. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
10. Kelly, B. P., S. K. Furney, M. T. Jessen, and I. M. Orme. 1996. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2809-2812.
11. Kirk, R. E. 1986. Experimental design: procedures for the behavioral sciences. Brooks-Cole Publishing Co., Belmont, Calif.
12. Klemens, S. P., and M. H. Cynamon. 1996. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 40:298-301.
13. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38:2245-2248.
14. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479.
15. Kochi, A. 1991. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72:1-6.
16. McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445-468.
17. Moghazeh, S. L., X. Pan, T. Arain, C. K. Stover, J. M. Musser, and B. N. Kreiswirth. 1996. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 48:2655-2657.
18. Mor, N., B. Simon, N. Mezo, and L. Heifets. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
19. Stead, W. W. 1967. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am. Rev. Respir. Dis. 95:729-745.
20. Stead, W. W., G. R. Kerby, D. P. Schleuter, and C. W. Jordahl. 1968. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann. Intern. Med. 68:731-745.
21. Vernon, A., A. Khan, L. Bozeman, and Y. C. Wang. 1998. Update on US Public Health Service (USPHS) study 22: a trial of once weekly isoniazid (INH) & rifapentine (RFP) in the continuation phase of TB treatment. Am. J. Respir. Crit. Care Med. 157:A467.
22. Wayne, L. G. 1994. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13:908-914.
23. World Health Organization. 1997. Treatment of tuberculosis: guidelines for national programmes, 2nd ed. World Health Organization publication no. TB/97.220. World Health Organization, Geneva, Switzerland.